CriticalAntiviral for systemic use, HIV-1 protease inhibitor; used only with a pharmacokinetic booster (ritonavir or cobicistat)×Ergot alkaloid, 5-HT1B/1D and alpha-adrenoceptor agonist
Updated · Methodology
Mechanism
Darunavir is taken only with a booster, ritonavir or cobicistat, and in this regimen it slows the clearance of drugs that depend heavily on CYP3A (darunavir summary of product characteristics, SmPC, European Medicines Agency, EMA). CYP3A4 inhibitors raise dihydroergotamine blood levels and with them the risk of vasospasm leading to ischaemia of the brain and limbs (dihydroergotamine labels, US Food and Drug Administration, FDA). With the strong inhibitor itraconazole, exposure to dihydroergotamine itself rose by 14–19%, while exposure to its active metabolite, an equally potent venoconstrictor, rose about 3- to 4-fold (dihydroergotamine FDA labels). Serious and life-threatening ischaemia has occurred when dihydroergotamine was combined with strong CYP3A4 inhibitors, including human immunodeficiency virus (HIV) protease inhibitors (dihydroergotamine FDA labels). The darunavir labels link this combination to acute ergot toxicity with peripheral vasospasm and ischaemia of the limbs and other tissues (darunavir FDA labels).
Symptoms
With excess dihydroergotamine, the arms and legs become numb, tingling and painful, the fingers and toes turn cold, pale or bluish, and pulses in the arms and legs weaken or disappear (dihydroergotamine label, US Food and Drug Administration, FDA). Leg ischaemia causes cramping and pain in the legs or hips, heaviness or tightness in the leg muscles, burning or aching pain in the feet or toes at rest, and coldness or colour change in one or both legs. Brain ischaemia causes slurred speech and sudden weakness (dihydroergotamine label, FDA). Myocardial and colonic ischaemia have also been reported. Severe poisoning causes nausea, vomiting, abdominal pain, respiratory depression, a rise and then usually a fall in blood pressure, confusion, delirium, seizures and coma (dihydroergotamine labels, FDA). Persistent vasospasm in people with poor circulation can lead to gangrene or death (dihydroergotamine label, FDA).
Management
The combination is contraindicated. Dihydroergotamine and other ergot derivatives are on the darunavir contraindication list with either booster, ritonavir or cobicistat, including the fixed-dose darunavir/cobicistat tablet (darunavir and darunavir/cobicistat summaries of product characteristics, SmPCs, European Medicines Agency, EMA; darunavir and darunavir/cobicistat labels, US Food and Drug Administration, FDA). The dihydroergotamine labels, for their part, contraindicate strong CYP3A4 inhibitors and give human immunodeficiency virus (HIV) protease inhibitors, such as ritonavir, as examples (dihydroergotamine FDA labels). Dihydroergotamine is not authorised in Spain, so there is no Spanish SmPC for it. Review all concomitant medicines for interactions before and during darunavir treatment (darunavir FDA label). Tell the patient to stop dihydroergotamine and get emergency help at once if they develop cramping and pain in the legs, numbness, coldness or colour change in the legs, slurred speech or sudden weakness (dihydroergotamine FDA label). If both drugs have nevertheless been taken and signs of vasospasm appear, stop dihydroergotamine at once (dihydroergotamine FDA label). In overdose, stop dihydroergotamine, support and monitor vital functions, and observe the patient for at least 24 hours or for as long as symptoms persist. Warm the affected area, give vasodilators and provide nursing care to prevent tissue damage (dihydroergotamine FDA labels).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Prezista (darunavir) prescribing information (2025)– FDA, DailyMed, setid 814301f9-c990-46a5-b481-2879a521a16f, SPL 08/2025 (Revised 03/2023), sections 4 and 7 (Table 10)
- EMA: Ficha técnica: Darunavir (Prezista, EU/1/06/380), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 106380007 (EU/1/06/380), secciones 4.3 y 4.5, consultado 10/2026
- FDA: ATZUMI (dihydroergotamine) prescribing information (2026)– FDA, DailyMed setid 0982a44a-dc0c-75c0-e063-6394a90a6d6c, revisión 06/2026 (versión 3), secciones 4, 5.5, 5.6 y 7.2
- FDA: TRUDHESA (dihydroergotamine) prescribing information (2026)– FDA, DailyMed setid b81397b0-910d-4eb4-8fee-a9a3c9d94d63, revisión 09/2026 (versión 7), secciones 4 y 7.2
- FDA: PREZCOBIX (darunavir and cobicistat) prescribing information (2026)– FDA, DailyMed setid 9c38fdb6-d0ba-4f16-a0e3-85d9ec334d9f (Janssen Products), revisión 02/2026 (versión 29), secciones 4, 6.2, 7.1 y 7.3
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.3 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, sección 4.3